Reactive Astrocytes Derived From Human Induced Pluripotent Stem Cells Suppress Oligodendrocyte Precursor Cell Differentiation.
astrocyte
induced pluripotent stem cell (iPSC)
multiple sclerosis
neurotoxicity
oligodendrocyte
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
02
2022
accepted:
28
03
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Astrocytes are instrumental in maintaining central nervous system (CNS) homeostasis and responding to injury. A major limitation of studying neurodegenerative diseases like multiple sclerosis (MS) is lack of human pathological specimens obtained during the acute stages, thereby relegating research to post-mortem specimens obtained years after the initiation of pathology. Rodent reactive astrocytes have been shown to be cytotoxic to neurons and oligodendrocytes but may differ from human cells, especially in diseases with genetic susceptibility. Herein, we purified human CD49f
Identifiants
pubmed: 35600072
doi: 10.3389/fnmol.2022.874299
pmc: PMC9120968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
874299Subventions
Organisme : NEI NIH HHS
ID : K99 EY029011
Pays : United States
Organisme : NEI NIH HHS
ID : R00 EY029011
Pays : United States
Informations de copyright
Copyright © 2022 Smith, Chamling, Gill, Martinez, Li, Fitzgerald, Sotirchos, Moroziewicz, Bauer, Paull, Gharagozloo, Bhargava, Zack, Fossati and Calabresi.
Déclaration de conflit d'intérêts
ES reports: scientific advisory board and/or consulting for Viela Bio, Horizon Therapeutics, Genentech, and Alexion; speaking fees from Alexion, Viela Bio, and Biogen. PC reports: PI on grants to JHU from Genentech and Principia; consulting fees from Biogen, Disarm Therapeutics (now owned by Lilly), and Avidia Technologies (now Vaccitech). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
STAR Protoc. 2020 Nov 10;1(3):100172
pubmed: 33377066
Glia. 2013 Apr;61(4):453-65
pubmed: 23322421
Nucleic Acids Res. 2021 Jan 8;49(D1):D325-D334
pubmed: 33290552
J Neurocytol. 1991 May;20(5):420-30
pubmed: 1869880
Nat Commun. 2019 Aug 29;10(1):3887
pubmed: 31467299
Acta Neuropathol. 2019 Dec;138(6):987-1012
pubmed: 31363836
Nat Methods. 2015 Sep;12(9):885-92
pubmed: 26237226
Glia. 2005 Aug 15;51(3):235-40
pubmed: 15812814
Trends Immunol. 2021 Mar;42(3):228-247
pubmed: 33593693
Glia. 2005 Nov 1;52(2):127-43
pubmed: 15920731
PLoS One. 2020 Jun 8;15(6):e0233980
pubmed: 32511247
Acta Neuropathol Commun. 2020 Feb 18;8(1):19
pubmed: 32070434
Nature. 2017 Jan 26;541(7638):481-487
pubmed: 28099414
Nat Med. 2018 Dec;24(12):1837-1844
pubmed: 30420755
Nat Neurosci. 2021 Oct;24(10):1475-1487
pubmed: 34413515
Nature. 2020 Feb;578(7796):593-599
pubmed: 32051591
Am J Pathol. 2015 Sep;185(9):2431-40
pubmed: 26193667
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nature. 1984 Jan 19-25;307(5948):273-6
pubmed: 6198590
Nature. 2021 Nov;599(7883):102-107
pubmed: 34616039
Lancet. 2017 Dec 2;390(10111):2481-2489
pubmed: 29029896
Nat Commun. 2016 Apr 26;7:11312
pubmed: 27115988
Nat Commun. 2021 Jan 28;12(1):652
pubmed: 33510160
PLoS Comput Biol. 2020 Feb 25;16(2):e1007664
pubmed: 32097405
Exp Neurol. 2008 Feb;209(2):294-301
pubmed: 17617407
Nat Neurosci. 2019 Dec;22(12):2087-2097
pubmed: 31768052
Front Immunol. 2018 Feb 19;9:217
pubmed: 29515568
Acta Neuropathol. 2021 Nov;142(5):899-915
pubmed: 34487221
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
J Exp Med. 2005 Jul 4;202(1):145-56
pubmed: 15998793
J Neurosci. 2021 Mar 10;41(10):2245-2263
pubmed: 33472827
J Neurosci. 2012 May 2;32(18):6391-410
pubmed: 22553043
Neuron. 2010 Nov 18;68(4):668-81
pubmed: 21092857
Genome Biol. 2020 Sep 7;21(1):239
pubmed: 32894187
J Neurosci. 2004 Mar 3;24(9):2143-55
pubmed: 14999065
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):5028-5038
pubmed: 32071226
Stem Cell Rev Rep. 2015 Aug;11(4):652-65
pubmed: 25951995
Nature. 2021 Sep;597(7878):709-714
pubmed: 34497421
Immunity. 2017 Jun 20;46(6):957-967
pubmed: 28636962
Biostatistics. 2017 Apr 1;18(2):275-294
pubmed: 27756721
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Wellcome Open Res. 2021 May 18;6:118
pubmed: 34660910
Neuron. 2020 Aug 5;107(3):436-453.e12
pubmed: 32485136
J Neurosci. 2009 Sep 16;29(37):11511-22
pubmed: 19759299
Brain. 2013 Jan;136(Pt 1):147-67
pubmed: 23266461
Nat Neurosci. 2021 Mar;24(3):312-325
pubmed: 33589835
Brain. 2013 Jan;136(Pt 1):116-31
pubmed: 23365094
Front Mol Neurosci. 2022 May 03;15:870085
pubmed: 35592112
Nat Med. 2005 Sep;11(9):966-72
pubmed: 16086023
Neuron. 2017 Dec 6;96(5):1003-1012.e7
pubmed: 29103804
Nat Protoc. 2015 Aug;10(8):1143-54
pubmed: 26134954
J Neurosci. 2011 Apr 20;31(16):6053-8
pubmed: 21508230
J Neurosci. 2008 Oct 8;28(41):10434-42
pubmed: 18842903
Mol Cell Neurosci. 2020 Dec;109:103565
pubmed: 33068719
Lancet Neurol. 2017 Mar;16(3):189-199
pubmed: 28229892
Cell Stem Cell. 2018 Aug 02;23(2):239-251.e6
pubmed: 30075130
Neurology. 2009 Jun 2;72(22):1914-21
pubmed: 19487649
Acta Neuropathol Commun. 2020 Dec 24;8(1):224
pubmed: 33357244
Neuron. 2013 Mar 6;77(5):873-85
pubmed: 23473318
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Front Immunol. 2020 Sep 30;11:573256
pubmed: 33117368
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
Trends Immunol. 2020 Sep;41(9):805-819
pubmed: 32800705
Science. 2021 Apr 23;372(6540):
pubmed: 33888612
Glia. 2021 Jun;69(6):1341-1368
pubmed: 33247866
Glia. 2020 Sep;68(9):1910-1924
pubmed: 32108971
Ann Neurol. 2015 Nov;78(5):710-21
pubmed: 26239536
Lancet Neurol. 2021 Sep;20(9):709-720
pubmed: 34418398
Nat Neurosci. 2018 May;21(5):683-695
pubmed: 29556031
Glia. 2019 Jan;67(1):68-77
pubmed: 30453391
Nat Biotechnol. 2015 May;33(5):495-502
pubmed: 25867923